Abstract
Cedartolen® is the first product for sublingual immunotherapy in Japan. It was approved in 2014 as an allergen immunotherapy product which would provide cure for allergic patients. It has some characteristics such as sublingual administration rout, dose escalation manner for reducing allergic reaction and so on. Furthermore we achieved the development of the container to store allergen extract solution stable and to administrate it with dose escalation manner. We expect that much more Japanese cedar pollinosis patients receive Cedartolen® treatment and they become relieved although three to five years treatment is required.
